<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"><channel><title><![CDATA[GLP-1 Studio: GLP-1 Studio Daily]]></title><description><![CDATA[Four GLP-1 stories from the last 24 hours, facts only, read by Amanda Bonello. New every morning at 7am Central.]]></description><link>https://newsletter.glp1studio.com/s/glp-1-studio-daily</link><image><url>https://substackcdn.com/image/fetch/$s_!yJhR!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F48bdba6e-b8a2-44bc-9fe4-8a5403cc8ba3_1254x1254.png</url><title>GLP-1 Studio: GLP-1 Studio Daily</title><link>https://newsletter.glp1studio.com/s/glp-1-studio-daily</link></image><generator>Substack</generator><lastBuildDate>Sun, 22 Nov 2026 12:59:06 GMT</lastBuildDate><atom:link href="https://newsletter.glp1studio.com/feed" rel="self" type="application/rss+xml"/><copyright><![CDATA[GLP-1 Studio LLC]]></copyright><language><![CDATA[en]]></language><webMaster><![CDATA[media@glp1studio.com]]></webMaster><itunes:owner><itunes:email><![CDATA[media@glp1studio.com]]></itunes:email><itunes:name><![CDATA[Amanda Bonello]]></itunes:name></itunes:owner><itunes:author><![CDATA[Amanda Bonello]]></itunes:author><googleplay:owner><![CDATA[media@glp1studio.com]]></googleplay:owner><googleplay:email><![CDATA[media@glp1studio.com]]></googleplay:email><googleplay:author><![CDATA[Amanda Bonello]]></googleplay:author><itunes:block><![CDATA[Yes]]></itunes:block><item><title><![CDATA[What happened to food cravings when people stepped down to 5 milligrams of tirzepatide?]]></title><description><![CDATA[In SURMOUNT-MAINTAIN, stepping down to 5 milligrams of tirzepatide kept food cravings low, while cravings returned within 12 weeks on placebo.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-20-2026-lower-dose-tirzepatide-food-cravings</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-20-2026-lower-dose-tirzepatide-food-cravings</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Fri, 20 Nov 2026 13:01:10 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/225752664/d509c2ec79dd1e0ed594df690df5a5db.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!Iynb!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!Iynb!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!Iynb!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!Iynb!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!Iynb!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!Iynb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/a87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:877038,&quot;alt&quot;:&quot;Close crop of a person holding a sugary donut in one hand and a green apple in the other, face not shown&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="Close crop of a person holding a sugary donut in one hand and a green apple in the other, face not shown" title="Close crop of a person holding a sugary donut in one hand and a green apple in the other, face not shown" srcset="https://substackcdn.com/image/fetch/$s_!Iynb!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!Iynb!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!Iynb!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!Iynb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa87be01a-995b-43a4-8e57-008d5200f9be_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Andres Ayrton on Pexels</figcaption></figure></div><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>Cutting back to a lower dose of tirzepatide kept food cravings down in a trial presented at ObesityWeek (<a href="https://www.endocrinologyadvisor.com/reports/lower-dose-tirzepatide-sustains-food-craving-suppression/">Endocrinology Advisor</a>)</p></li><li><p>Dairy makers say people on GLP-1s are part of why protein demand keeps climbing (<a href="https://www.foodnavigator.com/Article/2026/11/19/arla-danone-glp-1s-drive-dairy-protein-demand/">FoodNavigator</a>)</p></li><li><p>Health Canada has signed off on Foundayo, a daily GLP-1 pill from Eli Lilly (<a href="https://globalnews.ca/news/12156896/health-canada-approves-eli-lilly-glp1/">Global News (The Canadian Press)</a>)</p></li><li><p>A Penn trial tested semaglutide in adults with obesity, including some with binge eating (<a href="https://www.phillyvoice.com/glp-1-drugs-binge-eating-obesity/">PhillyVoice</a>)</p></li></ol></div><div><hr></div><h2>Cutting back to a lower dose of tirzepatide kept food cravings down in a trial presented at ObesityWeek</h2><p><strong>Key Details:</strong></p><ul><li><p>In the SURMOUNT-MAINTAIN trial, adults took the drug for 60 weeks at the highest dose they could handle, then were randomly assigned to stay on that dose, step down to 5 milligrams, or switch to a placebo for another 52 weeks.</p></li><li><p>Both groups still on the drug kept their lower scores for food cravings and hedonic hunger, which was measured with a scale called the Power of Food Scale.</p></li><li><p>Twelve weeks after switching to placebo, hedonic hunger and cravings were back to where they started, while weight came back more slowly.</p></li><li><p>The authors wrote that hedonic hunger and food cravings "may serve as early indicators of treatment withdrawal effects in adults with obesity."</p></li></ul><p>Source: <a href="https://www.endocrinologyadvisor.com/reports/lower-dose-tirzepatide-sustains-food-craving-suppression/">Endocrinology Advisor</a></p><div><hr></div><h2>Dairy makers say people on GLP-1s are part of why protein demand keeps climbing</h2><p><strong>Key Details:</strong></p><ul><li><p>Danone, Arla, Yili and Saputo have all pointed to weight-loss drugs as important for protein demand.</p></li><li><p>Tom Booijink, a dairy specialist at Rabobank, said whey is "at the forefront" of that demand.</p></li><li><p>He called the drugs a "very powerful catalyst" in an already tight market, but not the "sole driver."</p></li><li><p>A Danone spokesperson said the drugs are a key part of the company's push into high-protein products, especially because users want to keep their muscle mass.</p></li></ul><p>Source: <a href="https://www.foodnavigator.com/Article/2026/11/19/arla-danone-glp-1s-drive-dairy-protein-demand/">FoodNavigator</a></p><div><hr></div><h2>Health Canada has signed off on Foundayo, a daily GLP-1 pill from Eli Lilly</h2><p><strong>Key Details:</strong></p><ul><li><p>The agency authorized it on November 13 for adults with obesity, and for adults who are overweight with at least one related health problem, like high blood pressure or sleep apnea.</p></li><li><p>The pill is also approved to help treat Type 2 diabetes, and its active ingredient is orforglipron.</p></li><li><p>Lilly spokesperson Ethan Pigott said the company expects the pills to be in pharmacies in January.</p></li><li><p>Novo Nordisk's Wegovy pill is still waiting for approval in Canada.</p></li></ul><p>Source: <a href="https://globalnews.ca/news/12156896/health-canada-approves-eli-lilly-glp1/">Global News (The Canadian Press)</a></p><div><hr></div><h2>A Penn trial tested semaglutide in adults with obesity, including some with binge eating</h2><p><strong>Key Details:</strong></p><ul><li><p>The 160 adults got the drug or a placebo for 60 weeks, plus counseling on eating and exercise.</p></li><li><p>The semaglutide group lost about four times as much weight as the placebo group.</p></li><li><p>Among people who had binge eating before the study, more on the drug went into remission than on placebo.</p></li><li><p>Senior author Jena Tronieri said the findings suggest semaglutide "not only supports weight loss but may also improve several measures of eating disorder psychopathology and loss of control eating in many patients."</p></li></ul><p>Source: <a href="https://www.phillyvoice.com/glp-1-drugs-binge-eating-obesity/">PhillyVoice</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[What did a survey of 8,500 people find about GLP-1s and household food and drink?]]></title><description><![CDATA[A Dunnhumby survey of 8,500 people found almost 1 in 3 US adults say GLP-1 use shapes how they eat and drink. Plus CDC, Medicaid and FDA news.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-19-2026-glp1-food-drink-habits</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-19-2026-glp1-food-drink-habits</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Thu, 19 Nov 2026 19:42:25 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/225700532/60bc06ec41d2d65dd4b6a71a9eaed115.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!GmYt!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!GmYt!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!GmYt!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!GmYt!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!GmYt!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!GmYt!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1336871,&quot;alt&quot;:&quot;A family of three choosing fresh produce together in a grocery store.&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="A family of three choosing fresh produce together in a grocery store." title="A family of three choosing fresh produce together in a grocery store." srcset="https://substackcdn.com/image/fetch/$s_!GmYt!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!GmYt!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!GmYt!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!GmYt!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F77c58d84-6d34-44ef-b01d-269d1e3d61f2_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Greta Hoffman on Pexels</figcaption></figure></div><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>A customer data firm says each GLP-1 user shapes what more than two people at home eat and drink (<a href="https://www.just-drinks.com/news/glp-1s-shape-diets-of-one-in-five-adults-in-americas-study-shows/">Just Drinks</a>)</p></li><li><p>A CDC survey found about 2 in 5 GLP-1 users took their medicine differently than prescribed (<a href="https://medicalxpress.com/news/2026-11-adults-glp-medication-july-august.html">Medical Xpress</a> and <a href="https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm">CDC MMWR</a>)</p></li><li><p>In four states that ended Medicaid coverage of GLP-1s for weight loss, prescriptions fell about 84 percent compared with states that kept it (<a href="https://www.news-medical.net/news/20261116/Medicaid-coverage-cuts-sharply-reduce-weight-loss-drug-prescriptions.aspx">News-Medical</a> and <a href="https://jamanetwork.com/journals/jama/fullarticle/2856802">JAMA</a>)</p></li><li><p>Telehealth companies are getting FDA warning letters over how they describe compounded GLP-1s (<a href="https://www.medicaldaily.com/fda-warning-letters-compounded-glp1-telehealth-claims-481400">Medical Daily</a>)</p></li></ol></div><div><hr></div><h2>A customer data firm says each GLP-1 user shapes what more than two people at home eat and drink</h2><p><strong>Key Details:</strong></p><ul><li><p>The firm, Dunnhumby, surveyed 8,500 people in August across six countries: the US, Canada, Mexico, Brazil, Colombia and Chile.</p></li><li><p>Across those countries, about 10 percent of adults had used a GLP-1, and about 21 percent said the drugs shape their food and drink choices.</p></li><li><p>In the US, close to 17 percent of adults had used one, and almost 1 in 3 said GLP-1 use influenced their eating and drinking habits.</p></li><li><p>Among adults thinking about starting a GLP-1, cost was the most common reason they had not yet, at about 27 percent.</p></li></ul><p>Source: <a href="https://www.just-drinks.com/news/glp-1s-shape-diets-of-one-in-five-adults-in-americas-study-shows/">Just Drinks</a></p><div><hr></div><h2>A CDC survey found about 2 in 5 GLP-1 users took their medicine differently than prescribed</h2><p><strong>Key Details:</strong></p><ul><li><p>The report ran in the CDC's Morbidity and Mortality Weekly Report, using survey answers collected in July and August 2025.</p></li><li><p>About 1 in 10 US adults said they had taken a GLP-1 in the past year.</p></li><li><p>About 1 in 5 users said they used a compounded version, which the FDA does not review for safety, effectiveness or quality before it is sold.</p></li><li><p>The authors wrote, "Modifications in GLP-1 medication use reflect, in part, responses to cost- and access-related challenges."</p></li></ul><p>Source: <a href="https://medicalxpress.com/news/2026-11-adults-glp-medication-july-august.html">Medical Xpress</a> and <a href="https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm">CDC MMWR</a></p><div><hr></div><h2>In four states that ended Medicaid coverage of GLP-1s for weight loss, prescriptions fell about 84 percent compared with states that kept it</h2><p><strong>Key Details:</strong></p><ul><li><p>California, New Hampshire, Pennsylvania and South Carolina ended that coverage on January 1, 2026, and University of Pittsburgh researchers compared them with 10 other states.</p></li><li><p>Pennsylvania had the largest drop, at 95.5 percent, followed by New Hampshire at 88 percent.</p></li><li><p>The researchers estimate that between 175,500 and 526,600 fewer people on Medicaid may have filled a prescription.</p></li><li><p>Senior author Timothy Anderson said, "It is not surprising that abruptly ending drug coverage creates major disruptions in care."</p></li></ul><p>Source: <a href="https://www.news-medical.net/news/20261116/Medicaid-coverage-cuts-sharply-reduce-weight-loss-drug-prescriptions.aspx">News-Medical</a> and <a href="https://jamanetwork.com/journals/jama/fullarticle/2856802">JAMA</a></p><div><hr></div><h2>Telehealth companies are getting FDA warning letters over how they describe compounded GLP-1s</h2><p><strong>Key Details:</strong></p><ul><li><p>The latest round, announced June 16, was 25 letters about compounded semaglutide and tirzepatide, and in one case liraglutide.</p></li><li><p>Those letters flagged labels with the telehealth company's name, claims that the products were FDA-approved, and pharmacies described as "FDA-approved" or "FDA-licensed."</p></li><li><p>Earlier letters cited phrases like "Generic Zepbound," and the article notes that compounded drugs are not generics.</p></li><li><p>As of May 31, the FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, and those reports alone do not prove harm.</p></li></ul><p>Source: <a href="https://www.medicaldaily.com/fda-warning-letters-compounded-glp1-telehealth-claims-481400">Medical Daily</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[Who gets GLP-1s without a prior auth?]]></title><description><![CDATA[Only 3.7% of insured adults seeking semaglutide for weight loss had coverage with no prior authorization, an ObesityWeek study found.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-17-2026-glp1-prior-authorization</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-17-2026-glp1-prior-authorization</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Wed, 18 Nov 2026 13:08:22 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/225498226/faf91dd97ae7ac82804587f3f1c1cb46.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!KxSs!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!KxSs!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!KxSs!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!KxSs!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!KxSs!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!KxSs!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:664209,&quot;alt&quot;:&quot;Close-up of a doctor and a patient going over medical documents together during a consultation.&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="Close-up of a doctor and a patient going over medical documents together during a consultation." title="Close-up of a doctor and a patient going over medical documents together during a consultation." srcset="https://substackcdn.com/image/fetch/$s_!KxSs!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!KxSs!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!KxSs!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!KxSs!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4cb04441-1a81-4019-b17d-45499f0a804f_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Vitaly Gariev on Pexels</figcaption></figure></div><p>Good morning! Few insured adults could get GLP-1 drugs for weight loss without a prior approval step. Also today: a leptin pill that cut mouse weight 36% with semaglutide, teens on tirzepatide lowering BMI 19 points more than placebo, and a shot built for monthly to quarterly dosing. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>Few insured adults could get GLP-1 drugs for weight loss without a prior approval step (<a href="https://www.medicaldaily.com/glp1-weight-loss-drug-coverage-prior-authorization-study-481288">Medical Daily</a>)</p></li><li><p>An experimental leptin pill added to semaglutide boosted weight loss in obese mice (<a href="https://www.prnewswire.com/news-releases/in-combination-with-a-glp-1-erx-pharmaceuticals-first-in-class-oral-leptin-sensitizer-erx1000-showed-significantly-enhanced-weight-loss-improved-overall-metabolic-health-and-increased-muscle-strength-in-diet-induced-obese-mi-302939963.html">PR Newswire</a>)</p></li><li><p>Teens on tirzepatide lowered their BMI more than teens on placebo in a Lilly-funded trial (<a href="https://www.healio.com/news/endocrinology/20261116/tirzepatide-confers-robust-weight-loss-for-adolescents-with-obesity">Healio</a>)</p></li><li><p>The company shared early animal results for three experimental weight-loss drugs at ObesityWeek (<a href="https://www.prnewswire.com/news-releases/ascletis-highlights-oral-and-long-acting-injectable-anti-obesity-preclinical-studies-at-obesityweek-2026-302940205.html">PR Newswire</a>)</p></li></ol></div><div><hr></div><h2>Few insured adults could get GLP-1 drugs for weight loss without a prior approval step</h2><p><strong>Key Details:</strong></p><ul><li><p>The study used 2025 insurance checks from one telehealth company, and it has not been published in a journal.</p></li><li><p>Only 3.7 percent of commercially insured adults seeking semaglutide for weight management had coverage with no prior authorization. For tirzepatide, it was 2.8 percent.</p></li><li><p>Of 69,462 requests to start treatment, 53.2 percent were approved and 35.7 percent were denied.</p></li><li><p>Just over half of the denials, 51.1 percent, came from plan exclusions or coverage limits.</p></li></ul><p>Source: <a href="https://www.medicaldaily.com/glp1-weight-loss-drug-coverage-prior-authorization-study-481288">Medical Daily</a></p><div><hr></div><h2>An experimental leptin pill added to semaglutide boosted weight loss in obese mice</h2><p><strong>Key Details:</strong></p><ul><li><p>Dr. Louis Aronne of Weill Cornell Medicine, who sits on the company's board, presented the results November 15 at ObesityWeek in Washington, D.C.</p></li><li><p>After 35 days, the combination cut body weight by 36 percent after accounting for placebo, compared with 18 percent for the pill, ERX1000, alone and 14 percent for semaglutide alone.</p></li><li><p>Aronne said the combination "may mean patients can lower their GLP-1 dose and reduce accompanying side effects."</p></li><li><p>The pill is now in a Phase 2a trial in people with obesity, expected to finish in the second half of 2027.</p></li></ul><p>Source: <a href="https://www.prnewswire.com/news-releases/in-combination-with-a-glp-1-erx-pharmaceuticals-first-in-class-oral-leptin-sensitizer-erx1000-showed-significantly-enhanced-weight-loss-improved-overall-metabolic-health-and-increased-muscle-strength-in-diet-induced-obese-mi-302939963.html">PR Newswire</a></p><div><hr></div><h2>Teens on tirzepatide lowered their BMI more than teens on placebo in a Lilly-funded trial</h2><p><strong>Key Details:</strong></p><ul><li><p>The trial included 160 teens aged 12 to 17 with obesity or overweight, who got a weekly shot or a placebo for 72 weeks, along with lifestyle support. The results were presented at ObesityWeek and published in JAMA.</p></li><li><p>BMI fell 19 percentage points more with the drug than with placebo, and 48.1 percent of teens on it cut their BMI by 20 percent or more, compared with 7.9 percent on placebo.</p></li><li><p>Stomach and gut side effects affected 81.5 percent of teens on the drug, and 9.3 percent stopped because of side effects.</p></li><li><p>Dr. Claudia Fox of the University of Minnesota said, "There are no signals of disruption to growth and maturation in this trial."</p></li></ul><p>Source: <a href="https://www.healio.com/news/endocrinology/20261116/tirzepatide-confers-robust-weight-loss-for-adolescents-with-obesity">Healio</a></p><div><hr></div><h2>The company shared early animal results for three experimental weight-loss drugs at ObesityWeek</h2><p><strong>Key Details:</strong></p><ul><li><p>In monkeys, a combination pill called ASC30_48 cut body weight by 10.5 percent by day nine, compared with 6.9 percent for ASC30 alone and 1.7 percent for ASC48 alone.</p></li><li><p>A shot called ASC37 is designed to be given once a month to once every three months. Its half-life in monkeys was 372 hours, about 15 and a half days, compared with 57.8 hours for retatrutide.</p></li><li><p>In obese mice given daily shots, the highest dose of ASC37 cut body weight by 41.5 percent by day 12, compared with 4.7 percent for mice given an inactive shot.</p></li><li><p>The company's lead drug, a once-daily GLP-1 pill called ASC30, is in two global Phase 3 obesity trials.</p></li></ul><p>Source: <a href="https://www.prnewswire.com/news-releases/ascletis-highlights-oral-and-long-acting-injectable-anti-obesity-preclinical-studies-at-obesityweek-2026-302940205.html">PR Newswire</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[What happened when Medicaid cut GLP-1s?]]></title><description><![CDATA[A JAMA study found GLP-1 weight loss prescriptions on Medicaid fell from 2,914 to 421 per 100,000 in four states after coverage ended January 1, 2026.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-18-2026-medicaid-glp1-coverage</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-18-2026-medicaid-glp1-coverage</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Wed, 18 Nov 2026 13:01:09 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/225455853/d7ed10b2cf2e0cb3d905d3cd0fedef06.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!-DwX!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!-DwX!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!-DwX!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!-DwX!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!-DwX!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!-DwX!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:768892,&quot;alt&quot;:&quot;A semaglutide injection pen on a plain background&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="A semaglutide injection pen on a plain background" title="A semaglutide injection pen on a plain background" srcset="https://substackcdn.com/image/fetch/$s_!-DwX!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!-DwX!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!-DwX!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!-DwX!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F92321bdf-46cf-487a-9b4d-a17ac7ed3612_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Haberdoedas Photography on Pexels</figcaption></figure></div><p>Good morning! GLP-1 prescriptions for weight loss fell sharply in four states after Medicaid stopped paying for them. Also today: a JAMA summit report on insurance barriers to obesity care, 5.4% vs 13.5% lung disease with GLP-1s in systemic sclerosis, and an FDA filing for a weekly four-target obesity pill. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>GLP-1 prescriptions for weight loss fell sharply in four states after Medicaid stopped paying for them (<a href="http://readme.readmedia.com/Second-year-Geisinger-medical-student-co-authors-JAMA-study-on-GLP-1s/merit-207952">ReadMedia</a> and <a href="https://www.medicaldaily.com/medicaid-glp1-prescriptions-fell-after-coverage-ended-481317">Medical Daily</a>)</p></li><li><p>A JAMA summit report lays out insurance, drug and food policy steps to go with obesity medicines (<a href="https://www.ajmc.com/view/glp-1s-alone-won-t-solve-obesity-jama-summit-report-says">AJMC</a>)</p></li><li><p>People with systemic sclerosis and obesity who took GLP-1s had fewer lung problems in a look back at health records (<a href="https://www.healio.com/news/rheumatology/20261116/glp1s-may-reduce-pulmonary-complications-patients-with-systemic-sclerosis-obesity">Healio</a>)</p></li><li><p>Ascletis asked the FDA to let it start testing a weekly pill aimed at four obesity targets (<a href="https://www.prnewswire.com/news-releases/ascletis-submits-ind-application-to-the-us-fda-for-asc3637o-fdc-a-potentially-first-in-class-once-weekly-oral-quadruple-peptide-agonist-targeting-amylin-receptor-glp-1r-gipr-and-gcgr-for-the-treatment-of-obesity-302941638.html">PR Newswire</a>)</p></li></ol></div><div><hr></div><h2>GLP-1 prescriptions for weight loss fell sharply in four states after Medicaid stopped paying for them</h2><p><strong>Key Details:</strong></p><ul><li><p>The study came out in JAMA on November 16, and a second-year student at Geisinger College's School of Medicine is one of its authors.</p></li><li><p>California, New Hampshire, Pennsylvania and South Carolina ended Medicaid coverage of GLP-1s for weight loss on January 1, 2026.</p></li><li><p>In those states, prescriptions per 100,000 people on Medicaid went from 2,914 in the last three months of 2025 to 421 in the first three months of 2026.</p></li><li><p>Pennsylvania had the steepest drop, at 95.5 percent.</p></li></ul><p>Source: <a href="http://readme.readmedia.com/Second-year-Geisinger-medical-student-co-authors-JAMA-study-on-GLP-1s/merit-207952">ReadMedia</a> and <a href="https://www.medicaldaily.com/medicaid-glp1-prescriptions-fell-after-coverage-ended-481317">Medical Daily</a></p><div><hr></div><h2>A JAMA summit report lays out insurance, drug and food policy steps to go with obesity medicines</h2><p><strong>Key Details:</strong></p><ul><li><p>The report says the insurance system discourages obesity treatment by not covering it or by requiring heavy prior authorization.</p></li><li><p>It says the Medicare GLP-1 Bridge and a Medicaid program called BALANCE could be expanded if they work.</p></li><li><p>The authors also called for stronger enforcement against compounded copies of FDA-approved drugs when there is no shortage.</p></li><li><p>They wrote, "no single intervention will be enough."</p></li></ul><p>Source: <a href="https://www.ajmc.com/view/glp-1s-alone-won-t-solve-obesity-jama-summit-report-says">AJMC</a></p><div><hr></div><h2>People with systemic sclerosis and obesity who took GLP-1s had fewer lung problems in a look back at health records</h2><p><strong>Key Details:</strong></p><ul><li><p>Researchers compared 1,578 pairs of patients who did or did not use GLP-1s, and presented the results at ACR Convergence in Orlando.</p></li><li><p>Over 10 years, 5.4 percent of GLP-1 users developed interstitial lung disease, compared with 13.5 percent of non-users.</p></li><li><p>Pulmonary hypertension, high blood pressure in the lungs, showed up in 6.5 percent of users and 15.1 percent of non-users.</p></li><li><p>Dr. Aseed Mestarihi of the University of Central Florida said, "We acknowledge that these results are not practice changing, and that these are just hypothesis-generating."</p></li></ul><p>Source: <a href="https://www.healio.com/news/rheumatology/20261116/glp1s-may-reduce-pulmonary-complications-patients-with-systemic-sclerosis-obesity">Healio</a></p><div><hr></div><h2>Ascletis asked the FDA to let it start testing a weekly pill aimed at four obesity targets</h2><p><strong>Key Details:</strong></p><ul><li><p>The Hong Kong-listed company filed an Investigational New Drug application, the request to begin human trials, for a pill code-named ASC36_37o FDC.</p></li><li><p>The tablet combines two drugs that act on the amylin, GLP-1, GIP and glucagon receptors.</p></li><li><p>In rat studies, the combination led to about 69 percent more weight loss than one of those drugs alone.</p></li><li><p>The company has also started a US phase one study of a related pill, ASC36o, with first data on how the drug moves through the body expected by the end of 2026.</p></li></ul><p>Source: <a href="https://www.prnewswire.com/news-releases/ascletis-submits-ind-application-to-the-us-fda-for-asc3637o-fdc-a-potentially-first-in-class-once-weekly-oral-quadruple-peptide-agonist-targeting-amylin-receptor-glp-1r-gipr-and-gcgr-for-the-treatment-of-obesity-302941638.html">PR Newswire</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[How long did one amylin dose last in rats?]]></title><description><![CDATA[Prolynx says one amylin dose kept up weight loss in obese rats for 12 weeks, data it says could support obesity medicines dosed every three months.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-16-2026-long-acting-obesity-drugs</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-16-2026-long-acting-obesity-drugs</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Mon, 16 Nov 2026 13:01:00 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/225120060/ecab3106995287dc3abc060f4bee0309.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!eiMe!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!eiMe!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!eiMe!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!eiMe!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!eiMe!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!eiMe!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:883939,&quot;alt&quot;:&quot;Close-up of a white lab mouse held in a gloved hand&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="Close-up of a white lab mouse held in a gloved hand" title="Close-up of a white lab mouse held in a gloved hand" srcset="https://substackcdn.com/image/fetch/$s_!eiMe!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!eiMe!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!eiMe!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!eiMe!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F6431dab0-ee65-4945-a5de-7a22a0a97a6b_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Pixabay on Pexels</figcaption></figure></div><p>Good morning! Prolynx shares rat data it says could support obesity medicines dosed once every three months. Also today: a surgeon on more temple filler after GLP-1 weight loss, a Crewe man charged over Mounjaro at a drug distributor, and two-year weight changes after five next steps in 20,486 people. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>Prolynx shares rat data it says could support obesity medicines dosed once every three months (<a href="https://www.manilatimes.net/2026/11/15/tmt-newswire/globenewswire/prolynx-presents-preclinical-data-at-obesityweek-2026-supporting-the-potential-for-quarterly-dosing-of-ultra-long-acting-anti-obesity-peptides/2470161">The Manila Times</a>)</p></li><li><p>A surgeon reports more temple filler after GLP-1 weight loss (<a href="https://www.dailymail.com/lifestyle/beauty/article-16288533/melissa-rivers-temporal-hallowing-filler-plastic-surgery.html">Daily Mail</a>)</p></li><li><p>A Crewe man faces theft charges over Mounjaro at the drug distributor where he worked (<a href="https://www.warringtonguardian.co.uk/news/26726880.employee-charged-stealing-manjaro-warrington-firm/">Warrington Guardian</a>)</p></li><li><p>Cleveland Clinic researchers compare weight after five different next steps on GLP-1 shots (<a href="https://www.medscape.com/viewarticle/after-glp-1-which-exit-strategy-keeps-weight-2026a10018gh">Medscape</a>)</p></li></ol></div><div><hr></div><h2>Prolynx shares rat data it says could support obesity medicines dosed once every three months</h2><p><strong>Key Details:</strong></p><ul><li><p>The Emeryville, California, biotech presented three posters at ObesityWeek 2026 on Saturday, November 14.</p></li><li><p>In rats with diet-induced obesity, a single dose of an amylin drug kept up weight loss for 12 weeks.</p></li><li><p>A GLP-1 and GIP drug reached a half-life of more than one month.</p></li><li><p>Chief Executive Chris Boulton said: "... weekly injections and dosing-related side effects remain real barriers to long-term treatment."</p></li></ul><p>Source: <a href="https://www.manilatimes.net/2026/11/15/tmt-newswire/globenewswire/prolynx-presents-preclinical-data-at-obesityweek-2026-supporting-the-potential-for-quarterly-dosing-of-ultra-long-acting-anti-obesity-peptides/2470161">The Manila Times</a></p><div><hr></div><h2>A surgeon reports more temple filler after GLP-1 weight loss</h2><p><strong>Key Details:</strong></p><ul><li><p>Melissa Rivers, 58, told the New York Post she lost 25 pounds on Mounjaro in six months, then developed temporal hollowing, a sunken look at the temples.</p></li><li><p>She had collagen-stimulating filler injections and a radiofrequency skin-tightening treatment.</p></li><li><p>Facial plastic surgeon Dr. Lesley Rabach told the Daily Mail: "... there's been a significant uptick in both temple filler as well as temple fat transfer in patients who've had significant weight loss from GLP-1s."</p></li><li><p>Filler that lasts about a year can cost 5,000 to 7,000 dollars, she said, and fat transfers run 15,000 to 18,000.</p></li></ul><p>Source: <a href="https://www.dailymail.com/lifestyle/beauty/article-16288533/melissa-rivers-temporal-hallowing-filler-plastic-surgery.html">Daily Mail</a></p><div><hr></div><h2>A Crewe man faces theft charges over Mounjaro at the drug distributor where he worked</h2><p><strong>Key Details:</strong></p><ul><li><p>Jamie Taylor, 32, appeared at Warrington Magistrates' Court on Wednesday.</p></li><li><p>The charges are theft by an employee and handling stolen goods, between January 26 and March 13.</p></li><li><p>It is alleged he took the drug while working at AAH Pharmaceuticals, a health care distributor in Winwick Quay.</p></li><li><p>He has not entered a plea yet, remains on conditional bail, and is due back in court on November 24.</p></li></ul><p>Source: <a href="https://www.warringtonguardian.co.uk/news/26726880.employee-charged-stealing-manjaro-warrington-firm/">Warrington Guardian</a></p><div><hr></div><h2>Cleveland Clinic researchers compare weight after five different next steps on GLP-1 shots</h2><p><strong>Key Details:</strong></p><ul><li><p>The study used health records from 20,486 people at Cleveland Clinic centers in Ohio and Florida who started on semaglutide or tirzepatide, and it was presented at ObesityWeek.</p></li><li><p>After two years, weight was down 10.9 percent for people who stayed on their first medicine, 16 percent for those who switched between the two drugs, and 8.2 percent for those who moved to another obesity medicine.</p></li><li><p>Weight was down 28.2 percent after bariatric surgery and 4 percent for people who stopped their medicine.</p></li><li><p>The authors note the study was observational and say prospective real-world studies are needed to confirm the findings.</p></li></ul><p>Source: <a href="https://www.medscape.com/viewarticle/after-glp-1-which-exit-strategy-keeps-weight-2026a10018gh">Medscape</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[Why does a dietitian warn about scurvy?]]></title><description><![CDATA[Clare Collins says GLP-1 users need help with nutrient deficiencies to avoid scurvy, and her team is running a three-month dietitian trial.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-14-2026-glp1-nutrient-deficiencies</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-14-2026-glp1-nutrient-deficiencies</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Sat, 14 Nov 2026 13:01:51 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/224842622/09fd2fa99ad17f5f1db99f9b569eaaef.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!DIoN!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!DIoN!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!DIoN!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!DIoN!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!DIoN!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!DIoN!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:947680,&quot;alt&quot;:&quot;Freshly sliced orange halves showing their juicy inside&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="Freshly sliced orange halves showing their juicy inside" title="Freshly sliced orange halves showing their juicy inside" srcset="https://substackcdn.com/image/fetch/$s_!DIoN!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!DIoN!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!DIoN!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!DIoN!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f24ae73-1bd6-4325-815a-564158c3c8ce_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Jerms on Pexels</figcaption></figure></div><p>Good morning! An Australian dietitian is studying nutrition for people on GLP-1 drugs. Also today: UK GLP-1 households cutting grocery spending by 780 million pounds, 2.1 billion people eating like GLP-1 users, and a 27 percent lower risk of asthma flare-ups. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>An Australian dietitian is studying nutrition for people on GLP-1 drugs (<a href="https://www.newcastleherald.com.au/story/9390795/clare-collins-warns-weight-loss-drugs-like-ozempic-wegovy-and-mounjaro-could-trigger-return-of-scurvy/">Newcastle Herald</a>)</p></li><li><p>Drink makers get a list of ways to make products for people on GLP-1s (<a href="https://www.foodnavigator.com/Article/2026/11/13/how-glp-1s-are-changing-beverage-innovation/">FoodNavigator</a>)</p></li><li><p>A data company says far more people eat like GLP-1 users than take the drugs (<a href="https://www.foodnavigator.com/Article/2026/11/13/glp-1-halo-effect-a-2-billion-demand-pool/">FoodNavigator</a>)</p></li><li><p>GLP-1 drugs are linked to fewer asthma flare-ups in people with obesity (<a href="https://www.empr.com/reports/glp-1-ras-may-reduce-asthma-exacerbations-improve-control-in-obesity/">MPR</a>)</p></li></ol></div><div><hr></div><h2>An Australian dietitian is studying nutrition for people on GLP-1 drugs</h2><p><strong>Key Details:</strong></p><ul><li><p>Laureate Professor Clare Collins of the University of Newcastle said, "We've got to address the nutrient deficiencies, otherwise we'll see a return of scurvy and pellagra."</p></li><li><p>The article says those diseases come from severe shortages of vitamin C and B vitamins.</p></li><li><p>Researcher Rachael Taylor said, "The medication suppresses appetite, so people can eat about 50 per cent less than normal."</p></li><li><p>A review the team published in June found only two of 41 randomized controlled trials recorded what people ate.</p></li><li><p>Collins and her team are now running a three-month trial for adults in the Hunter region with type 2 diabetes who take these drugs, with up to five telehealth sessions with a dietitian.</p></li></ul><p>Source: <a href="https://www.newcastleherald.com.au/story/9390795/clare-collins-warns-weight-loss-drugs-like-ozempic-wegovy-and-mounjaro-could-trigger-return-of-scurvy/">Newcastle Herald</a></p><div><hr></div><h2>Drink makers get a list of ways to make products for people on GLP-1s</h2><p><strong>Key Details:</strong></p><ul><li><p>Thom Walton of the company Finlays writes that UK households using GLP-1s cut grocery spending by 780 million pounds, citing Worldpanel by Numerator.</p></li><li><p>His five ideas are less sugar, more protein and nutrients, help with hydration, gentler drinks for digestion, and smaller sizes like shots and small bottles.</p></li><li><p>He points to Smoothie King's GLP-1 support smoothies in the US and Danone's Oikos Fusion drinks.</p></li><li><p>Sei-Wai Tse, who manages scientific and regulatory affairs at Finlays, says "GLP-1 friendly" is not an authorized term and should be used with caution.</p></li></ul><p>Source: <a href="https://www.foodnavigator.com/Article/2026/11/13/how-glp-1s-are-changing-beverage-innovation/">FoodNavigator</a></p><div><hr></div><h2>A data company says far more people eat like GLP-1 users than take the drugs</h2><p><strong>Key Details:</strong></p><ul><li><p>Kline and Company estimates 2.1 billion people follow eating patterns that line up with GLP-1 use, compared with about 89 million people taking the drugs worldwide.</p></li><li><p>Elizabeth Thundow, a vice president at the firm, explains that the people in this group have a strong concern about metabolic health.</p></li><li><p>Kline says 10 billion dollars a year of US food spending is already moving toward yogurt, meat snacks, nutrition bars and fresh fruit.</p></li><li><p>The article says lifestyle nutrition and dairy are likely to gain, while snacks, bakery and breakfast cereals may lose out.</p></li></ul><p>Source: <a href="https://www.foodnavigator.com/Article/2026/11/13/glp-1-halo-effect-a-2-billion-demand-pool/">FoodNavigator</a></p><div><hr></div><h2>GLP-1 drugs are linked to fewer asthma flare-ups in people with obesity</h2><p><strong>Key Details:</strong></p><ul><li><p>Researchers from the University of Houston pooled five earlier studies with more than 73,000 people.</p></li><li><p>In three of those studies, all of people with obesity, GLP-1 use was tied to a 27 percent lower risk of asthma flare-ups.</p></li><li><p>Teens on these drugs had fewer asthma visits to the emergency room and fewer steroid prescriptions.</p></li><li><p>The authors say randomized trials are still needed to confirm the results and check safety.</p></li></ul><p>Source: <a href="https://www.empr.com/reports/glp-1-ras-may-reduce-asthma-exacerbations-improve-control-in-obesity/">MPR</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[Which age group's eyelid surgery rose most?]]></title><description><![CDATA[About 119,000 eyelid surgeries were done in the U.S. in 2025, rising fastest among people 25 and under. Plus UK, Deloitte and Sunnyside GLP-1 news.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-13-2026-eyelid-surgery</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-13-2026-eyelid-surgery</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Fri, 13 Nov 2026 13:04:00 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/224688915/704724eef9ad9afb21aacfba38f5ec22.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!IaEE!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!IaEE!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!IaEE!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!IaEE!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!IaEE!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!IaEE!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/db8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1277158,&quot;alt&quot;:&quot;A close-up of a human eye showing the eyelid skin and eyelashes.&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="A close-up of a human eye showing the eyelid skin and eyelashes." title="A close-up of a human eye showing the eyelid skin and eyelashes." srcset="https://substackcdn.com/image/fetch/$s_!IaEE!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!IaEE!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!IaEE!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!IaEE!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdb8cb665-8928-4177-a20d-21d57830d53b_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by hartono subagio on Pexels</figcaption></figure></div><p>Good morning! Cosmetic eyelid surgery is rising fastest among people 25 and under. Also today: 311 UK reports of deaths linked to GLP-1 drugs, Deloitte's US health plans dropping GLP-1 weight loss coverage, and Sunnyside's semaglutide with naltrexone for heavy drinking. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>Cosmetic eyelid surgery is rising fastest among people 25 and under (<a href="https://www.the-independent.com/life-style/health-and-families/belpharoplasty-plastic-surgery-young-adults-us-b3083377.html">The Independent</a>)</p></li><li><p>UK reports of deaths linked to GLP-1 drugs have reached 311, with the most among people in their 60s (<a href="https://www.dailymail.com/health/article-16284355/weight-loss-jab-deaths-middle-aged-users-GLP-1-risk.html">Daily Mail</a>)</p></li><li><p>Deloitte's US health plans will drop GLP-1 coverage for weight loss (<a href="https://www.businessinsider.com/deloitte-benefits-cuts-glp-1-coverage-healthcare-costs-rise-2026-11">Business Insider</a>)</p></li><li><p>Sunnyside now offers semaglutide with naltrexone for heavy drinking (<a href="https://www.prnewswire.com/news-releases/sunnyside-adds-glp-1-options-to-its-medication-program-for-alcohol-use-disorder-after-treating-more-than-15-000-people-in-18-months-302937033.html">PR Newswire</a>)</p></li></ol></div><div><hr></div><h2>Cosmetic eyelid surgery is rising fastest among people 25 and under</h2><p><strong>Key Details:</strong></p><ul><li><p>About 119,000 of these surgeries were done in the U.S. in 2025, up 19 percent from 2024, the American Society of Plastic Surgeons says.</p></li><li><p>Fewer young adults have the surgery than people over 45, but their yearly rise was the biggest.</p></li><li><p>The article says the increase has been traced to social media, celebrities and GLP-1 drugs, which can cause a sunken look called "Ozempic face."</p></li><li><p>The outpatient procedure costs 3,000 dollars, and insurance covers it only when drooping skin blocks vision.</p></li></ul><p>Source: <a href="https://www.the-independent.com/life-style/health-and-families/belpharoplasty-plastic-surgery-young-adults-us-b3083377.html">The Independent</a></p><div><hr></div><h2>UK reports of deaths linked to GLP-1 drugs have reached 311, with the most among people in their 60s</h2><p><strong>Key Details:</strong></p><ul><li><p>The count comes from the Yellow Card scheme run by the MHRA, the UK medicines regulator, and is up from 216 in August.</p></li><li><p>The reports do not show the drugs caused the deaths, only that someone suspected they may have played a role.</p></li><li><p>There were 88 reported deaths among people in their 60s and 20 among people in their 40s, even though people in their 40s are about three and a half times more likely to be prescribed the drugs.</p></li><li><p>Dr Alex Miras of Imperial College London said, "People in older age groups have a higher chance of dying anyway."</p></li></ul><p>Source: <a href="https://www.dailymail.com/health/article-16284355/weight-loss-jab-deaths-middle-aged-users-GLP-1-risk.html">Daily Mail</a></p><div><hr></div><h2>Deloitte's US health plans will drop GLP-1 coverage for weight loss</h2><p><strong>Key Details:</strong></p><ul><li><p>The change is in an internal benefits guide seen by the outlet, and the drugs stay covered for diabetes and other covered conditions.</p></li><li><p>For weight loss, the firm will offer a virtual program called eMed, with coaching and a 125 dollar employer contribution per prescription.</p></li><li><p>Most plans will also have higher deductibles and out-of-pocket maximums.</p></li><li><p>The firm, which employs about 181,000 people in the US, told staff the changes "reflect the hard trade-offs of today's cost environment."</p></li></ul><p>Source: <a href="https://www.businessinsider.com/deloitte-benefits-cuts-glp-1-coverage-healthcare-costs-rise-2026-11">Business Insider</a></p><div><hr></div><h2>Sunnyside now offers semaglutide with naltrexone for heavy drinking</h2><p><strong>Key Details:</strong></p><ul><li><p>The company launched two programs on November 12, at 199 dollars a month for a microdose and 299 dollars a month for a full dose, plus a one-time 50 dollar intake fee.</p></li><li><p>Naltrexone has been FDA-approved for alcohol dependence since 1994, but semaglutide is not FDA-approved to treat alcohol use disorder.</p></li><li><p>The medications are compounded, and the release notes the FDA does not review compounded drugs for safety, effectiveness or quality.</p></li><li><p>CEO Nick Allen said, "It's clear that medication can quiet the urge to drink in the moment, but it won't change the ingrained habits around drinking on its own."</p></li></ul><p>Source: <a href="https://www.prnewswire.com/news-releases/sunnyside-adds-glp-1-options-to-its-medication-program-for-alcohol-use-disorder-after-treating-more-than-15-000-people-in-18-months-302937033.html">PR Newswire</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[What happened after two men quit tirzepatide?]]></title><description><![CDATA[Two men had mood and psychotic symptoms after stopping tirzepatide. Also: GLP-1 brain aging trials, 200+ drugs in development, a Mounjaro theft case.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-12-2026-stopping-tirzepatide-symptoms</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-12-2026-stopping-tirzepatide-symptoms</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Thu, 12 Nov 2026 13:01:27 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/224539703/15c30506478ca4324b8f02435ee85b0e.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!1cj_!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!1cj_!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!1cj_!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!1cj_!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!1cj_!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!1cj_!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:640969,&quot;alt&quot;:&quot;A psychologist and a patient talking during a therapy session indoors.&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="A psychologist and a patient talking during a therapy session indoors." title="A psychologist and a patient talking during a therapy session indoors." srcset="https://substackcdn.com/image/fetch/$s_!1cj_!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!1cj_!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!1cj_!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!1cj_!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44188727-86a8-40c3-ab86-0a4d66f53bc5_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Vitaly Gariev on Pexels</figcaption></figure></div><p>Good morning! Two men developed mood and psychotic symptoms after they stopped taking tirzepatide. Also today: a brain aging trial in 180 generally healthy adults, more than 200 GLP-1 drugs in development, and a Boots worker sentenced over Mounjaro. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>Two men developed mood and psychotic symptoms after they stopped taking tirzepatide (<a href="https://www.psychiatrist.com/pcc/mood-psychotic-symptoms-rapid-discontinuation-glp-1-agonist/">Primary Care Companion for CNS Disorders</a>)</p></li><li><p>Two new trials will give GLP-1 drugs to mostly healthy older adults to study brain aging (<a href="https://www.medscape.com/viewarticle/why-we-may-soon-add-antiaging-glp-1s-growing-benefits-2026a100172j">Medscape</a>)</p></li><li><p>More than 200 drugs in the GLP-1 and incretin class are now in development (<a href="https://www.manilatimes.net/2026/11/12/tmt-newswire/globenewswire/glp-1-ras-incretin-based-therapies-competitive-landscape-analysis-key-developments-by-200-companies-shaping-the-treatment-landscape-delveinsight/2467838">The Manila Times</a>)</p></li><li><p>A woman who worked at a Boots pharmacy admitted taking Mounjaro from the store (<a href="https://www.rhyljournal.co.uk/news/26719749.rhyl-woman-stole-3-400-mounjaro-boots-pharmacy/">Rhyl Journal</a>)</p></li></ol></div><div><hr></div><h2>Two men developed mood and psychotic symptoms after they stopped taking tirzepatide</h2><p><strong>Key Details:</strong></p><ul><li><p>Psychiatrists at the University of Pennsylvania described the two cases in a report published online October 22. Both men had a history of mental health conditions.</p></li><li><p>A 61-year-old man stopped the drug in August 2025 because of nausea. In October he was admitted with confusion, paranoia, and hallucinations he could hear and see.</p></li><li><p>A 52-year-old man stopped abruptly in September 2025 after losing 100 pounds over six months. He was later treated for manic symptoms, and his vitamin B12 level was low.</p></li><li><p>The authors wrote that stopping the drug "may contribute" to these symptoms in some at-risk patients, and that it "may represent an underrecognized clinical phenomenon."</p></li></ul><p>Source: <a href="https://www.psychiatrist.com/pcc/mood-psychotic-symptoms-rapid-discontinuation-glp-1-agonist/">Primary Care Companion for CNS Disorders</a></p><div><hr></div><h2>Two new trials will give GLP-1 drugs to mostly healthy older adults to study brain aging</h2><p><strong>Key Details:</strong></p><ul><li><p>A trial from Vero Bioscience and the Atria Health and Research Institute is recruiting people aged 50 to 75 in stable health. The treatment group takes tirzepatide for six months, up to 10 milligrams a week, and the main measure is brain age from a protein test made by Vero co-founder Tony Wyss-Coray of Stanford. About 22 people are expected to take part.</p></li><li><p>A larger trial in Switzerland called PROMOTE, starting later this year, will include 180 people aged 50 to 70 who are generally healthy but have at least two risk factors, like borderline high blood pressure or prediabetes. It will compare the drug with a placebo for a year, and the drug has not been chosen yet.</p></li><li><p>No large drug company has said it wants to test GLP-1s in healthy people, so these trials come from startups and university groups.</p></li><li><p>Heike Bischoff-Ferrari of the University of Basel, one of the PROMOTE researchers, said "generally healthy" does not mean "without risk."</p></li></ul><p>Source: <a href="https://www.medscape.com/viewarticle/why-we-may-soon-add-antiaging-glp-1s-growing-benefits-2026a100172j">Medscape</a></p><div><hr></div><h2>More than 200 drugs in the GLP-1 and incretin class are now in development</h2><p><strong>Key Details:</strong></p><ul><li><p>The firm counts over 180 companies working on them, with more than 30 in late-stage testing.</p></li><li><p>Besides obesity and type 2 diabetes, they are being tested for knee osteoarthritis pain, sleep apnea, and chronic low back pain.</p></li><li><p>In June, China's drug regulator accepted Hansoh's application for olatorepatide for chronic weight management.</p></li></ul><p>Source: <a href="https://www.manilatimes.net/2026/11/12/tmt-newswire/globenewswire/glp-1-ras-incretin-based-therapies-competitive-landscape-analysis-key-developments-by-200-companies-shaping-the-treatment-landscape-delveinsight/2467838">The Manila Times</a></p><div><hr></div><h2>A woman who worked at a Boots pharmacy admitted taking Mounjaro from the store</h2><p><strong>Key Details:</strong></p><ul><li><p>Justine Ettery, 55, pleaded guilty to theft by an employee at Llandudno Magistrates Court on Wednesday.</p></li><li><p>She took Mounjaro worth 3,492 pounds from the Prestatyn branch between April and July 2025.</p></li><li><p>She received an eight-month prison sentence, suspended for a year and a half.</p></li><li><p>No compensation was ordered because she had already paid the money back to Boots.</p></li></ul><p>Source: <a href="https://www.rhyljournal.co.uk/news/26719749.rhyl-woman-stole-3-400-mounjaro-boots-pharmacy/">Rhyl Journal</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[What did stopping GLP-1s do to heart risk?]]></title><description><![CDATA[An Italian study links stopping GLP-1s to more heart attacks and strokes. Plus pregnancy guidance, an oral GLP-1 study and a collagen program.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-11-2026-stopping-glp1-heart-risk</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-11-2026-stopping-glp1-heart-risk</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Wed, 11 Nov 2026 13:03:38 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/224391156/3ec66b5788d28e8a6765ae4faa058440.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!kTnc!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!kTnc!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!kTnc!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!kTnc!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!kTnc!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!kTnc!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:592364,&quot;alt&quot;:&quot;A black stethoscope lying on a light blue background&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="A black stethoscope lying on a light blue background" title="A black stethoscope lying on a light blue background" srcset="https://substackcdn.com/image/fetch/$s_!kTnc!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!kTnc!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!kTnc!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!kTnc!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F62706665-9c57-4ccd-9a12-f25a13c74359_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Etatics Inc. on Pexels</figcaption></figure></div><p>Good morning! Stopping GLP-1s was linked to more heart attacks and strokes in people with type 2 diabetes. Also today: new GLP-1 pregnancy guidance from the American College of Obstetricians and Gynecologists, first human results coming for Biomea Fusion's GLP-1 taken by mouth, and a human collagen program pointing to GLP-1 weight loss. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>Stopping GLP-1s was linked to more heart attacks and strokes in people with type 2 diabetes (<a href="https://www.devonlive.com/news/uk-world-news/new-heart-attack-stroke-warning-11235199">Devon Live</a>)</p></li><li><p>The American College of Obstetricians and Gynecologists now advises stopping GLP-1s before pregnancy (<a href="https://www.npr.org/transcripts/nx-s1-6023369">NPR Short Wave</a>)</p></li><li><p>Biomea Fusion will present early results for BMF-650, a GLP-1 drug taken by mouth (Biomea Fusion)</p></li><li><p>Conexeu Sciences started a human collagen program for aesthetics, pointing to demand after GLP-1 weight loss (Conexeu Sciences)</p></li></ol></div><div><hr></div><h2>Stopping GLP-1s was linked to more heart attacks and strokes in people with type 2 diabetes</h2><p><strong>Key Details:</strong></p><ul><li><p>Researchers in Italy and at Guy's and St Thomas' NHS Foundation Trust in London used records from more than 300 Italian diabetes clinics, covering more than 80,000 people with type 2 diabetes on GLP-1 drugs.</p></li><li><p>The risk of a non-fatal heart attack, a non-fatal stroke or death from any cause was about twice as high for those who came off the drugs. The team said that is about four cases per 100 people a year, compared with two per 100 among those who kept taking them.</p></li><li><p>People who continued were on the drugs for nearly three years on average, and those who quit for just over one year.</p></li><li><p>Writing in the journal Lancet Regional Health Europe, the researchers stressed the study was observational, so the people who stopped may already have been in poorer health, and it did not look at why they stopped. Dr Faye Riley of Diabetes UK said "Anyone with type 2 diabetes who is considering stopping treatment should speak to their healthcare team first."</p></li></ul><p>Source: <a href="https://www.devonlive.com/news/uk-world-news/new-heart-attack-stroke-warning-11235199">Devon Live</a></p><div><hr></div><h2>The American College of Obstetricians and Gynecologists now advises stopping GLP-1s before pregnancy</h2><p><strong>Key Details:</strong></p><ul><li><p>The group released the guidance in October to help OB/GYNs counsel their patients about these drugs and pregnancy.</p></li><li><p>Amy Valent, an OB/GYN at Oregon Health and Science University who worked on the guidance, said that means one or two months ahead, depending on how long each drug stays in the body.</p></li><li><p>She said tirzepatide, sold as Mounjaro and Zepbound, has been shown to lower some of how well birth control pills work. Her advice is a backup barrier method for a month when starting or changing the dose, or a method that is not a pill, like an IUD or an arm implant.</p></li><li><p>Questions about GLP-1s, fertility and pregnancy come up often in her clinic. "It probably comes up every other patient."</p></li></ul><p>Source: <a href="https://www.npr.org/transcripts/nx-s1-6023369">NPR Short Wave</a></p><div><hr></div><h2>Biomea Fusion will present early results for BMF-650, a GLP-1 drug taken by mouth</h2><p><strong>Key Details:</strong></p><ul><li><p>The phase 1 results come from the drug's first study in people. They will be shown as a poster at the ObesityWeek 2026 conference in National Harbor, Maryland, on Monday, November 16.</p></li><li><p>The announcement does not share any of the results. The company says the poster will go on its website after the conference ends.</p></li><li><p>BMF-650 is investigational, which means it is not approved.</p></li></ul><p>Source: <a href="https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/biomea-fusion-announces-poster-presentation-of-phase-1-results-for-bmf-650-its-investigational-next-generation-oral-small-molecule-glp-1-receptor-agonist-at-obesityweek-2026/2466266">Biomea Fusion press release (The Manila Times)</a></p><div><hr></div><h2>Conexeu Sciences started a human collagen program for aesthetics, pointing to demand after GLP-1 weight loss</h2><p><strong>Key Details:</strong></p><ul><li><p>Its first step was a pilot batch of human type one collagen. The company says it met its own specifications in internal testing that has not been independently checked or peer reviewed.</p></li><li><p>The collagen is for CXU, an injectable the company is developing. It goes in as a liquid, sets into a gel at body temperature, and becomes a temporary scaffold the body remodels into its own tissue.</p></li><li><p>None of this is approved, and its 12-month study was in animals. The company plans to submit its lead device, Ten Minute Tissue, to the FDA in early 2027 with wound care as its first use, and any product made with human collagen would need a separate review.</p></li><li><p>Chief executive Miles Harrison said "GLP-1 has created a new patient profile: people whose bodies have changed faster than today's aesthetic injectables were built to address, and restoring that tissue takes more than volume."</p></li></ul><p>Source: <a href="https://www.manilatimes.net/2026/11/10/tmt-newswire/globenewswire/conexeu-sciences-launches-human-collagen-initiative-for-regenerative-aesthetics-as-glp-1-drives-demand-for-tissue-restoration/2466474">Conexeu Sciences press release (The Manila Times)</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[What did the FDA find on GLP-1s and NAION?]]></title><description><![CDATA[The FDA will require a rare eye condition warning on every GLP-1 drug. Plus a sheep pregnancy study, fermented foods, and GLP-1 fragrance spending.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-10-2026-naion-eye-warning</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-10-2026-naion-eye-warning</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Tue, 10 Nov 2026 13:01:04 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/224236411/8e9e0c084d82c73011199b4dec48dee1.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!-f6H!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!-f6H!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!-f6H!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!-f6H!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!-f6H!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!-f6H!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:822394,&quot;alt&quot;:&quot;Black eyeglasses resting on an eye chart with rows of letters&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="Black eyeglasses resting on an eye chart with rows of letters" title="Black eyeglasses resting on an eye chart with rows of letters" srcset="https://substackcdn.com/image/fetch/$s_!-f6H!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!-f6H!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!-f6H!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!-f6H!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F70b46d91-48eb-483d-8f1f-71f341207625_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by Skyler Ewing on Pexels</figcaption></figure></div><p>Good morning! The FDA is requiring GLP-1 labels to warn about a rare eye condition called NAION. Also today: semaglutide lowered blood flow to the womb in pregnant sheep, a former Hindustan Unilever research director on fermented foods for GLP-1 users, and Givaudan says fine fragrance spending rose 97 percent in GLP-1 households. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>The FDA is requiring GLP-1 labels to warn about a rare eye condition called NAION (<a href="https://www.nbcnews.com/health/health-care/fda-orders-new-warning-glp-1s-rare-eye-condition-linked-sudden-blindne-rcna608309">NBC News</a>)</p></li><li><p>Semaglutide lowered blood flow to the womb in a study of pregnant sheep (<a href="https://www.miragenews.com/could-ozempic-and-wegovy-affect-unborn-babies-1774308/">Mirage News</a>)</p></li><li><p>A former Hindustan Unilever research director sees fermented foods as a fit for GLP-1 users (<a href="https://www.nutraingredients.com/Article/2026/11/09/unilever-ex-rd-lead-says-fermented-food-could-be-the-next-big-thing-for-glp-1-users/">NutraIngredients</a>)</p></li><li><p>Givaudan says fine fragrance spending rose 97 percent in U.S. households using GLP-1s (<a href="https://www.premiumbeautynews.com/en/the-new-desire-givaudan-explores,28508">Premium Beauty News</a>)</p></li></ol></div><div><hr></div><h2>The FDA is requiring GLP-1 labels to warn about a rare eye condition called NAION</h2><p><strong>Key Details:</strong></p><ul><li><p>On Monday, the FDA said every GLP-1 drug must add the warning to its label, including Ozempic, Wegovy, Mounjaro and Zepbound.</p></li><li><p>NAION is linked to reduced blood flow to the front of the optic nerve, which carries signals from the eye to the brain. It can cause sudden vision loss in one eye, and NBC News reports it is permanent with no known treatment.</p></li><li><p>In a review of 126 clinical trials, the FDA counted 15 probable cases, 10 in people on GLP-1s and 5 on placebo. That is 6.4 cases for every 100,000 years of patient time on a GLP-1, compared with 3.8 on placebo or other blood sugar drugs.</p></li><li><p>The agency called it a "potential increased risk" and said its review of animal data did not show how the drugs could raise it. It says patients on GLP-1s with sudden vision changes in one eye should contact their health care professional right away.</p></li></ul><p>Source: <a href="https://www.nbcnews.com/health/health-care/fda-orders-new-warning-glp-1s-rare-eye-condition-linked-sudden-blindne-rcna608309">NBC News</a> and <a href="https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential">FDA</a></p><div><hr></div><h2>Semaglutide lowered blood flow to the womb in a study of pregnant sheep</h2><p><strong>Key Details:</strong></p><ul><li><p>Researchers at Adelaide University in Australia gave semaglutide, the active ingredient in Ozempic and Wegovy, to pregnant sheep and used MRI scans to measure the mother's heart and blood flow to the uterus before and after.</p></li><li><p>Within two hours, the mother's heart was pumping significantly less blood, and blood flow to the uterus and oxygen in the fetus went down.</p></li><li><p>The findings are early, have not been shown in humans, and were shared as a conference abstract in the journal Heart, Lung and Circulation. The report does not say how many sheep were used. Senior researcher Professor Janna Morrison said "Our findings suggest a potential risk to fetal development, but we haven't yet established whether these short-term changes affect fetal growth, what happens over a longer period of semaglutide use or whether similar effects could occur in human pregnancies."</p></li><li><p>The drug is not recommended during pregnancy, and women planning to get pregnant are advised to stop it beforehand.</p></li></ul><p>Source: <a href="https://www.miragenews.com/could-ozempic-and-wegovy-affect-unborn-babies-1774308/">Mirage News</a></p><div><hr></div><h2>A former Hindustan Unilever research director sees fermented foods as a fit for GLP-1 users</h2><p><strong>Key Details:</strong></p><ul><li><p>Rinka Banerjee, who used to lead research and development for Hindustan Unilever's foods business in South Asia, spoke to NutraIngredients at a food industry summit in Singapore last month. She now runs a food and nutrition consulting firm in Bangalore, India.</p></li><li><p>She said Asian companies could start a new trend with fermented products for people on GLP-1 drugs. "We ferment our grains and rice, and fermented products benefit the gut microbiome, which is a big opportunity for us."</p></li><li><p>She pointed to Yakult, saying "It's portion-controlled, dose-controlled and it's fermented," and "That ticks all the boxes for something that a GLP-1 user would be looking for."</p></li><li><p>These are her views, and the article does not cite a study of fermented foods in people taking GLP-1s. It does cite a review in the journal Nature Health that found stomach and gut side effects like nausea, vomiting, constipation and diarrhea are common with these drugs. The article says those side effects have driven demand for gut support products like fiber.</p></li></ul><p>Source: <a href="https://www.nutraingredients.com/Article/2026/11/09/unilever-ex-rd-lead-says-fermented-food-could-be-the-next-big-thing-for-glp-1-users/">NutraIngredients</a></p><div><hr></div><h2>Givaudan says fine fragrance spending rose 97 percent in U.S. households using GLP-1s</h2><p><strong>Key Details:</strong></p><ul><li><p>Givaudan is a fragrance and flavor company, and every figure here comes from the company. A NielsenIQ survey it presented found U.S. households on GLP-1 drugs are moving spending away from food and toward beauty, sports and travel.</p></li><li><p>Spending on fine fragrance in those households rose 97 percent. The article does not say over what time period or compared with what.</p></li><li><p>Studies the company compiled found the share of U.S. adults taking GLP-1s for weight loss went from 3 percent in 2024 to 11 percent in 2026.</p></li><li><p>From tracking what people say online, it found two kinds of scents that seem to appeal to GLP-1 users: gourmand scents, which smell like food or sweets, and fresh scents. Some people may turn away from certain smells because of nausea. Fr&#233;d&#233;ric Merlin, manager of the Givaudan Digital Factory in Paris, said "The mistake would be to think that GLP-1 only affects people under treatment."</p></li></ul><p>Source: <a href="https://www.premiumbeautynews.com/en/the-new-desire-givaudan-explores,28508">Premium Beauty News</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p style="text-align: center;"></p><p style="text-align: center;">This is a reader-supported publication, thank you so much for your support. </p><p style="text-align: center;">&#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:&quot;button-wrapper&quot;}" data-component-name="ButtonCreateButton"><a class="button primary button-wrapper" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item><item><title><![CDATA[How did GLP-1s compare with metformin?]]></title><description><![CDATA[In 256,492 adults with prediabetes, fewer on GLP-1 drugs developed diabetes than on metformin. Plus eating habits, Wegovy and MASH, and Allergan.]]></description><link>https://newsletter.glp1studio.com/p/glp1-news-today-november-9-2026</link><guid isPermaLink="false">https://newsletter.glp1studio.com/p/glp1-news-today-november-9-2026</guid><dc:creator><![CDATA[Amanda Bonello]]></dc:creator><pubDate>Mon, 09 Nov 2026 13:04:09 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/224104286/d6fa3ae12d2d9f2059e6784f6a8d19f3.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!DRfW!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!DRfW!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!DRfW!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!DRfW!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!DRfW!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!DRfW!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png" width="1080" height="1080" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/b7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1080,&quot;width&quot;:1080,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:518849,&quot;alt&quot;:&quot;A white blood glucose meter reading 103 mg/dL on a tan background&quot;,&quot;title&quot;:&quot;A white blood glucose meter reading 103 mg/dL on a tan background&quot;,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="A white blood glucose meter reading 103 mg/dL on a tan background" title="A white blood glucose meter reading 103 mg/dL on a tan background" srcset="https://substackcdn.com/image/fetch/$s_!DRfW!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 424w, https://substackcdn.com/image/fetch/$s_!DRfW!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 848w, https://substackcdn.com/image/fetch/$s_!DRfW!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 1272w, https://substackcdn.com/image/fetch/$s_!DRfW!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7143d16-fe93-4e95-bc54-5edb9c0f5285_1080x1080.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Photo by i-SENS, USA on Pexels</figcaption></figure></div><p>Good morning! GLP-1 drugs linked to lower diabetes and heart risk than metformin in people with prediabetes. Also today: how eating habits changed for 38 people starting semaglutide or tirzepatide, Wegovy liver results in 106 people with MASH without obesity, and two Allergan face studies in people on GLP-1s. Listen to me read them above, or read the key details below.</p><div class="callout-block" data-callout="true"><h4>Daily Roundup:</h4><ol><li><p>GLP-1 drugs linked to lower diabetes and heart risk than metformin in people with prediabetes (HCPLive)</p></li><li><p>A small study tracks how eating habits change in the first three months on semaglutide or tirzepatide (News-Medical)</p></li><li><p>Wegovy improved liver markers in people with MASH who do not have obesity (HCPLive)</p></li><li><p>Allergan reports two studies of face and skin treatments in people taking GLP-1 medications (Allergan Aesthetics)</p></li></ol></div><div><hr></div><h2>GLP-1 drugs linked to lower diabetes and heart risk than metformin in people with prediabetes</h2><p><strong>Key Details:</strong></p><ul><li><p>A study compared GLP-1 drugs with metformin in more than 256,000 adults with prediabetes and obesity, using health records from 104 institutions over about three years.</p></li><li><p>Blood sugar went back to normal in 37.3 percent of people on GLP-1 drugs and 29.3 percent of people on metformin.</p></li><li><p>Type 2 diabetes developed in 25.1 percent of people on GLP-1 drugs and 37 percent of people on metformin, and the GLP-1 group had a lower risk of heart failure, stroke and heart attack.</p></li><li><p>The study looked back at records, so it cannot prove the drugs caused the results, and it has not been peer reviewed, meaning outside scientists have not checked it yet. Dr. Vinicius de Sousa Barzon Serra of the Mayo Clinic said, &#8220;Metformin is still a first-line treatment choice.&#8221;</p></li></ul><p>Source: <a href="https://www.hcplive.com/view/glp-1-ras-linked-to-lower-diabetes-cv-risk-than-metformin-in-prediabetes">HCPLive</a></p><div><hr></div><h2>A small study tracks how eating habits change in the first three months on semaglutide or tirzepatide</h2><p><strong>Key Details:</strong></p><ul><li><p>Researchers in Italy and the United Kingdom followed 38 adults without diabetes who started semaglutide or tirzepatide.</p></li><li><p>After three months, people reported fewer cravings for sweet and savory foods, feeling fuller after meals, and eating fewer meals a day.</p></li><li><p>84 percent reported much smaller portions, and people lost an average of 7.2 kilograms, about 16 pounds.</p></li><li><p>The authors said smaller portions can mean less protein, fiber, fluid, vitamins and minerals, and called for nutrition monitoring. It was a small pilot study with no comparison group.</p></li></ul><p>Source: <a href="https://www.news-medical.net/news/20261108/GLP-1-weight-loss-drugs-may-change-what-you-crave-not-just-how-much-you-eat.aspx">News-Medical</a></p><div><hr></div><h2>Wegovy improved liver markers in people with MASH who do not have obesity</h2><p><strong>Key Details:</strong></p><ul><li><p>MASH is a serious liver disease with fat and inflammation in the liver that can lead to scarring. A new look at Novo Nordisk&#8217;s ESSENCE trial studied 106 people with MASH and liver scarring whose BMI was below 27.</p></li><li><p>After 72 weeks, people on Wegovy had better liver enzyme levels and better blood markers of scarring than people on placebo.</p></li><li><p>Dr. J&#246;rn Schattenberg, who presented the analysis, said, &#8220;we looked at the BMI below 27 and compared it to the other BMI categories, and the efficacy is actually the same.&#8221;</p></li><li><p>Novo Nordisk said this kind of after-the-fact analysis raises ideas that need more study.</p></li></ul><p>Source: <a href="https://www.hcplive.com/view/essence-semaglutide-improves-liver-markers-in-mash-without-obesity">HCPLive</a> and <a href="https://www.prnewswire.com/news-releases/novo-post-hoc-analysis-finds-wegovy-2-4-mg-was-associated-with-improvements-in-liver-markers-in-adults-with-mash-with-liver-scarring-and-a-bmi-less-than-27-kgm2--presented-at-the-liver-meeting-aasld-2026--302932759.html">Novo Nordisk</a></p><div><hr></div><h2>Allergan reports two studies of face and skin treatments in people taking GLP-1 medications</h2><p><strong>Key Details:</strong></p><ul><li><p>Allergan presented both studies at the American Society for Dermatologic Surgery meeting in San Diego. Both looked at its hyaluronic acid fillers in adults on steady doses of GLP-1 medications.</p></li><li><p>In one study, 30 people on GLP-1 medications got fillers, Botox and a skincare routine, and they reported higher satisfaction with how their face and skin looked.</p></li><li><p>Early results from the other study, covering 25 of its 75 people, found 95.7 percent were satisfied or very satisfied that they still looked like themselves.</p></li><li><p>Both studies tested Allergan&#8217;s own products, with no comparison group, and people rated the results themselves.</p></li></ul><p>Source: <a href="https://www.prnewswire.com/news-releases/allergan-aesthetics-reports-improved-satisfaction-with-facial-appearance-following-aesthetic-treatment-in-two-studies-of-patients-on-glp-1-medications-302932241.html">Allergan Aesthetics</a></p><div><hr></div><h2>Learn More</h2><ul><li><p>Join the free GLP-1 community Cozy Butter: <a href="https://cozybutter.com">cozybutter.com</a></p></li><li><p>Listen to GLP-1 Radio, GLP-1 shows all day: <a href="https://glp1radio.com">glp1radio.com</a></p></li><li><p>Every GLP-1 Studio Daily episode: <a href="https://newsletter.glp1studio.com/s/glp-1-studio-daily">GLP-1 Studio Daily</a></p></li><li><p>About Amanda Bonello: <a href="https://amandabonello.com">amandabonello.com</a></p></li></ul><div class="captioned-image-container"><figure><a class="image-link image2 image2-align-left" target="_blank" href="https://amandabonello.com" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png" width="240" height="240" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:240,&quot;width&quot;:240,&quot;resizeWidth&quot;:240,&quot;bytes&quot;:1175008,&quot;alt&quot;:&quot;Amanda Bonello&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:&quot;https://amandabonello.com&quot;,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:&quot;left&quot;,&quot;offset&quot;:false}" class="sizing-normal" alt="Amanda Bonello" title="Amanda Bonello" srcset="https://substackcdn.com/image/fetch/$s_!81s3!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 424w, https://substackcdn.com/image/fetch/$s_!81s3!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 848w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1272w, https://substackcdn.com/image/fetch/$s_!81s3!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F56f15748-2abe-4dfa-ad98-dd84fc6bb4be_800x800.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></a></figure></div><p></p><p></p><p>This is a reader-supported publication, thank you so much for your support. &#128150;</p><p style="text-align: center;"></p><p style="text-align: center;"></p><p class="button-wrapper" data-attrs="{&quot;url&quot;:&quot;https://newsletter.glp1studio.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe now&quot;,&quot;action&quot;:null,&quot;class&quot;:null}" data-component-name="ButtonCreateButton"><a class="button primary" href="https://newsletter.glp1studio.com/subscribe?"><span>Subscribe now</span></a></p><p style="text-align: center;"><a href="https://www.instagram.com/amanda.bonell0/">Instagram</a> &#183; <a href="https://www.tiktok.com/@amanda.bonello">TikTok</a> &#183; <a href="https://www.linkedin.com/in/amandabonello">LinkedIn</a></p><div><hr></div><h6><em>Disclaimer: I was not paid, sponsored, or compensated in any way for this episode or article. Nothing in this article, podcast, or platform should be used as a substitute for professional medical care, diagnosis, or treatment. Always consult with a qualified healthcare provider about your health decisions. I also do not formally endorse any news source, clinic, or company featured. </em></h6>]]></content:encoded></item></channel></rss>